About this trial
The goal of this clinical trial is to measure the median effective dose of oxycodone for the treatment of acute pain after thoracoscopic lobectomy. This clinical trial was divided into two groups based on age, Group I (Age \< 65 years old) and Group II (Age ≥65 years old). We used the sequential allocation designed by Dixon. The initial oxycodone dose was set to 0.1 mg/kg.A satisfactory or an unsatisfactory analgesic response of the previous patient determined, respectively, the relative 10% decrease or increase in the dose of oxycodone the next patient received in the same group. The patient before the first crossover point was included as the first case for ED50 estimation in each group.The study was conducted until 7 crossover points were collected
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The first unilateral thoracoscopic lobectomy was performed under general anesthesia
age 18- 80 years old
American Society of Anesthesiologists (ASA) physical status I-III
Sign the informed consent of the patients
Disqualifiers
Moderate to severe obesity (i.e., BMI > 30kg/m2)
Allergic or hypersensitive reaction to oxycodon
A history of chronic pain
Patients with significant heart, pulmonary, liver or renal disease
Trial design
Parallel
Treatments tested in this trial
Oxycodone will be administered intravenously in the group 1
DrugOxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
Treatment groups
Trial outcomes
Primary outcomes
The median effective dose
The median effective dose of oxycodone for the treatment of acute pain after thoracoscopic lobectomy
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Jianbo Wu
Lead sponsor
Qianfoshan Hospital
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: